rabbit anti mesothelin Search Results


90
ZSGB Biotech rabbit anti-human mesothelin antibody ep140
Miltefosine enhances CAR-T cell efficacy against solid tumors in vivo (A) Experimental timeline of CDX model and the fold change of tumor volume in CAR-T cell-treated CDX mouse model in the presence or absence of miltefosine administration (PBS group, n = 3; other groups, n = 5). (B) Tumor weight of each group at the end of experiment (PBS group, n = 3; other groups, n = 5). (C) The percentages of <t>mesothelin-</t> and hCD3-positive area in tumor tissues (PBS group, n = 2; other groups, n = 5). Scale bar: 200 μm. (D) The fold change of tumor volume in CDX mouse model treated with CAR-T cells derived from another donor, in the presence or absence of miltefosine or anti-PD-1 antibody treatment ( n = 4). (E) The proportion of hCD3 + T cells in the peripheral blood of CDX mouse model ( n = 4). (F) The fold change of tumor volume in CAR-T cell-treated PDX mouse model, in the presence or absence of miltefosine or anti-PD-1 antibody treatment ( n = 4). (G) The proportion of hCD3 + T cells in the peripheral blood of PDX mouse model ( n = 4). Unpaired t test was used in statistical analysis. (H) Experimental timeline of the OT-1-treated melanoma isograft tumor model. (I) The fold change in tumor volume in the OT-1-treated melanoma isograft tumor model in the presence or absence of miltefosine administration ( n = 7). Unpaired t test was used in statistical analysis. NS, not significant, ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001. All error bars denote SEM. See also <xref ref-type=Figure S7 . " width="250" height="auto" />
Rabbit Anti Human Mesothelin Antibody Ep140, supplied by ZSGB Biotech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rabbit+anti+mesothelin/pmc11722131-8-0-7?v=ZSGB+Biotech
Average 90 stars, based on 1 article reviews
rabbit anti-human mesothelin antibody ep140 - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier

86
Absolute Biotech Inc rabbit anti mesothelin
Miltefosine enhances CAR-T cell efficacy against solid tumors in vivo (A) Experimental timeline of CDX model and the fold change of tumor volume in CAR-T cell-treated CDX mouse model in the presence or absence of miltefosine administration (PBS group, n = 3; other groups, n = 5). (B) Tumor weight of each group at the end of experiment (PBS group, n = 3; other groups, n = 5). (C) The percentages of <t>mesothelin-</t> and hCD3-positive area in tumor tissues (PBS group, n = 2; other groups, n = 5). Scale bar: 200 μm. (D) The fold change of tumor volume in CDX mouse model treated with CAR-T cells derived from another donor, in the presence or absence of miltefosine or anti-PD-1 antibody treatment ( n = 4). (E) The proportion of hCD3 + T cells in the peripheral blood of CDX mouse model ( n = 4). (F) The fold change of tumor volume in CAR-T cell-treated PDX mouse model, in the presence or absence of miltefosine or anti-PD-1 antibody treatment ( n = 4). (G) The proportion of hCD3 + T cells in the peripheral blood of PDX mouse model ( n = 4). Unpaired t test was used in statistical analysis. (H) Experimental timeline of the OT-1-treated melanoma isograft tumor model. (I) The fold change in tumor volume in the OT-1-treated melanoma isograft tumor model in the presence or absence of miltefosine administration ( n = 7). Unpaired t test was used in statistical analysis. NS, not significant, ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001. All error bars denote SEM. See also <xref ref-type=Figure S7 . " width="250" height="auto" />
Rabbit Anti Mesothelin, supplied by Absolute Biotech Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rabbit+anti+mesothelin/pmc09197998-829-0-3?v=Absolute+Biotech+Inc
Average 86 stars, based on 1 article reviews
rabbit anti mesothelin - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier

N/A
Rabbit anti-Mesothelin(C-terminus) Antibody
  Buy from Supplier

N/A
Rabbit anti-Mesothelin(C-terminus) [+Biotin] Antibody, 50 µg
  Buy from Supplier

N/A
Mesothelin antibody [N1C2], 1 mg/ml (100 µl)
  Buy from Supplier

Image Search Results


Miltefosine enhances CAR-T cell efficacy against solid tumors in vivo (A) Experimental timeline of CDX model and the fold change of tumor volume in CAR-T cell-treated CDX mouse model in the presence or absence of miltefosine administration (PBS group, n = 3; other groups, n = 5). (B) Tumor weight of each group at the end of experiment (PBS group, n = 3; other groups, n = 5). (C) The percentages of mesothelin- and hCD3-positive area in tumor tissues (PBS group, n = 2; other groups, n = 5). Scale bar: 200 μm. (D) The fold change of tumor volume in CDX mouse model treated with CAR-T cells derived from another donor, in the presence or absence of miltefosine or anti-PD-1 antibody treatment ( n = 4). (E) The proportion of hCD3 + T cells in the peripheral blood of CDX mouse model ( n = 4). (F) The fold change of tumor volume in CAR-T cell-treated PDX mouse model, in the presence or absence of miltefosine or anti-PD-1 antibody treatment ( n = 4). (G) The proportion of hCD3 + T cells in the peripheral blood of PDX mouse model ( n = 4). Unpaired t test was used in statistical analysis. (H) Experimental timeline of the OT-1-treated melanoma isograft tumor model. (I) The fold change in tumor volume in the OT-1-treated melanoma isograft tumor model in the presence or absence of miltefosine administration ( n = 7). Unpaired t test was used in statistical analysis. NS, not significant, ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001. All error bars denote SEM. See also <xref ref-type=Figure S7 . " width="100%" height="100%">

Journal: Cell Reports Medicine

Article Title: Miltefosine reinvigorates exhausted T cells by targeting their bioenergetic state

doi: 10.1016/j.xcrm.2024.101869

Figure Lengend Snippet: Miltefosine enhances CAR-T cell efficacy against solid tumors in vivo (A) Experimental timeline of CDX model and the fold change of tumor volume in CAR-T cell-treated CDX mouse model in the presence or absence of miltefosine administration (PBS group, n = 3; other groups, n = 5). (B) Tumor weight of each group at the end of experiment (PBS group, n = 3; other groups, n = 5). (C) The percentages of mesothelin- and hCD3-positive area in tumor tissues (PBS group, n = 2; other groups, n = 5). Scale bar: 200 μm. (D) The fold change of tumor volume in CDX mouse model treated with CAR-T cells derived from another donor, in the presence or absence of miltefosine or anti-PD-1 antibody treatment ( n = 4). (E) The proportion of hCD3 + T cells in the peripheral blood of CDX mouse model ( n = 4). (F) The fold change of tumor volume in CAR-T cell-treated PDX mouse model, in the presence or absence of miltefosine or anti-PD-1 antibody treatment ( n = 4). (G) The proportion of hCD3 + T cells in the peripheral blood of PDX mouse model ( n = 4). Unpaired t test was used in statistical analysis. (H) Experimental timeline of the OT-1-treated melanoma isograft tumor model. (I) The fold change in tumor volume in the OT-1-treated melanoma isograft tumor model in the presence or absence of miltefosine administration ( n = 7). Unpaired t test was used in statistical analysis. NS, not significant, ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001. All error bars denote SEM. See also Figure S7 .

Article Snippet: Rabbit anti-human mesothelin Antibody (clone EP140) , ZSGB-BIO , Cat#ZA-0579.

Techniques: In Vivo, Derivative Assay

Journal: Cell Reports Medicine

Article Title: Miltefosine reinvigorates exhausted T cells by targeting their bioenergetic state

doi: 10.1016/j.xcrm.2024.101869

Figure Lengend Snippet:

Article Snippet: Rabbit anti-human mesothelin Antibody (clone EP140) , ZSGB-BIO , Cat#ZA-0579.

Techniques: Functional Assay, Flow Cytometry, Control, Recombinant, Lysis, Activation Assay, Transfection, Luciferase, Viability Assay, SYBR Green Assay, RNA Sequencing Assay, Construct, Plasmid Preparation, Software